3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
13
Phase 3
8
Phase 1/2
3
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
16
NIH
3
INDUSTRY
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Interventions
Carboplatin
272
Paclitaxel
267
Gemcitabine
244
Bevacizumab
225
Cisplatin
216
pembrolizumab
213
Docetaxel
210
Pemetrexed
162
Capecitabine
148
Fluorouracil
129
Oxaliplatin
121
Cyclophosphamide
121
Nivolumab
112
Dexamethasone
99
Trastuzumab
89
Leucovorin
87
Cetuximab
85
Rituximab
83
Irinotecan
82
Injections
80
Erlotinib Hydrochloride
70
Prednisone
68
Doxorubicin
68
Temozolomide
67
atezolizumab
65
Ipilimumab
64
Bortezomib
64
Fulvestrant
59
Radiotherapy
54
Drug Therapy
51
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
INDUSTRY
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts